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ABSTRACT: The ever-increasing prevalence of sulfoximine derivatives in drug discovery programmes has brought about a renais-
sance in the development of methods for their synthesis. Sulfoximine synthesis via C-S bond formation however has been compara-
tively underexplored. Herein, we report that sulfonimidates constitute a versatile precursor for the synthesis of medicinally relevant 
sulfoximines. 
In recent years, the synthesis of sulfoximines has drawn con-
siderable interest from academic research groups and pharma-
ceutical companies alike.1 The sulfoximine moiety has found 
success in a number of drug discovery programmes, for exam-
ple in the ATR inhibitor AZD 67381e and the anti-asthmatic 
Sudexanox1f (Figure 1). As part of our ongoing research pro-
gramme in the area of organosulfur chemistry, we have been 
interested in developing novel approaches to the synthesis of 
valuable sulfur(VI) compounds.2 Common methods for sul-
foximine synthesis3 largely stem from either the imination of 
sulfoxides,4 the oxidation of sulfilimines5 or directly from sul-
phides6 by a dual oxidation/imination protocol (Figure 1a). Each 
of these approaches however restrict the N-substituent on the 
resultant sulfoximine to those functionalities that can be incor-
porated into an iminating agent. Consequently, a somewhat step 
intensive: imination, (often N-deprotection) and then N-func-
tionalization sequence is commonly employed. To compliment 
this approach a number of methods for the functionalization of 
N-H sulfoximines have been developed.7 One alternative strat-
egy for sulfoximine formation is the displacement of a leaving 
group from a sulfur(VI) derivative with a carbon centred nucle-
ophile. Sulfonimidoyl halides have been trialled for this appli-
cation, but there are a number of challenges with this approach, 
for example the organomagnesium mediated reduction of sul-
fonimidolyl chlorides to sulfinimines.8a Recent reports from 
Sharpless highlight the utility of sulfonimidoyl fluorides for this 
application, which can be generated in two steps from SOF4 
gas.9 This is a powerful strategy however the preparation of 
SOF4 requires the handling of highly toxic gases at elevated 
temperature and pressure, a requirement that will likely deter 
many practitioners. Sulfonimidates on the other hand have only 
scarcely been employed for the preparation of sulfoximines. 
 
 
Figure 1. Examples of medicinally relevant sulfoximines 
(Top); a) Previous approaches to sulfoximine synthesis via sul-
fide oxidation/imination; b) This study: sulfinamides → sul-
fonimidates → sulfoximines 
 Our attention was drawn to isolated examples from the early 
literature8 where sulfonimidoyl chlorides were initially con-
verted to the corresponding sulfonimidates before reaction with 
an organometallic reagent to yield sulfoximines. The examples 
are few and limited to S-aryl sulfonimidates; in two instances8b,c 
alkyl lithium reagents are utilised but to the best of our 
knowledge there is only a single example, reported by Cram 
where an organomagnesium reagent has been used.8a Since 
these seminal reports, the field of sulfur(VI) chemistry has bur-
geoned and greatly improved methods for the synthesis of sul-
fonimidates have been developed,10 e.g. the oxidative alkoxyla-
tion of sulfinamides (Figure 2). In the context of these advances 
we surmised that a general method for the conversion of sul-
fonimidates to sulfoximines would offer a powerful and com-
plementary strategy for sulfoximine synthesis. 
 
Figure 2. Investigation into the substrate scope of sulfonimi-
date synthesis via iodosylbenzene mediated sulfinamide oxida-
tion. Reactions were performed on a 0.4 -1.9 mmol scale. Yields 
are for isolated products following chromatography. 
Initially, sulfonimidate formation was performed via oxida-
tion of the corresponding sulfinamides with iodosylbenzene in 
the presence of an excess of alcohol as solvent.10b-d The oxida-
tion of N-phenyl benzenesulfinamide proceeded smoothly both 
in ethanol and trifluoroethanol, to afford the desired sulfonimi-
dates 1 and 2 in good yields (75% and 69% respectively). As 
reported by Malacria,10b-d bond unsaturations are tolerated under 
the oxidising reaction conditions; this was confirmed by the for-
mation of O-propargyl and O-allyl sulfonimidates 3 and 4 (85% 
and 75% respectively, Figure 2). Previous studies are limited 
almost exclusively to S-phenyl and -tolyl substratates and we 
were keen to further investigate the scope of this transformation 
with regard to S-substitution.  Unfortunately, we were unable to 
form the S-tBu sulfonimidates 5 or 6 under these conditions, 
presumably due to steric hindrance. Furthermore, in contrast to 
the O-allyl example 4, incorporation of S-allyl functionality sig-
nificantly reduced the yield of the transformation (35% and 
38% obtained for 7 and 8 respectively). Pleasingly however, the 
medicinally relevant S-cyclopropyl derivatives 9 and 10 could 
be accessed in 88% and 79% respectively. For the purposes of 
many drug discovery programmes, low molecular weight frag-
ments are favoured so that screening compounds can be devel-
oped that populate “Lipinski space”.11 As such, we were de-
lighted to observe that the highest yields were obtained in the 
synthesis of S-methyl sulfonimidates 11 and 12 (92% and 81% 
yield respectively). Consequently, we selected N-phenyl me-
thanesulfinamide as a test substrate to further investigate the 
scope of the reaction with regard to the alcohol component. 
Pleasingly, a range of alkenyl and alkynyl alcohols were incor-
porated smoothly, affording the corresponding sulfonimidates 
13-20 in 62-93% (Figure 2). In their proposed role as an inter-
mediate for sulfoximine synthesis however, the “alkoxyl” sub-
stituent on the sulfonimidate core would serve as a leaving 
group so we selected ethanol and trifluoroethanol to screen the 
scope of sulfonimidate formation with regard to N-substitution. 
Initially the effect of incorporating electron-rich and -poor N-
aryl substituents was investigated. Pleasingly, para-methoxy, -
chloro and -trifluomethyl derivatives 21-26 could each be ob-
tained in modest to good yield (Figure 2). Next, we moved on 
to investigate N-alkyl substituents.  
 
Table 1. Optimisation of reaction conditions. Reactions were 
performed on a 0.2-0.5 mmol scale. Yields are for isolated prod-
ucts following chromatography. 
 
Entry SM Equiv. Solvent T (ºC) Yield 
(%) 
1 11 5 eq. Et2O 25 52 
2 11 5 eq. Et2O -78 55 
3 11 5 eq. Toluene -78 48 
4 11 5 eq. THF -78 65 
5 11 3 eq. THF -78 54 
6 11 1 eq. THF -78 31 
7 11 5 eq. THF -20 59 
8 11 5 eq. THF 0 41 
9 12 5 eq. THF -78 42 
 
 N-benzyl (27/28) and N-cyclohexyl (29/30) sulfonimidates 
were obtained in moderate to good yields (27-59%). Pleasingly, 
N-cyclopropyl, -tert-butyl and -trityl sulfonimidates 31-35 were 
also afforded, indicating that bulky groups are considerably bet-
ter tolerated on the nitrogen substituent than they are on the sul-
fur (Figure 2). Considering that the best yields for sulfonimidate 
formation were obtained with N-aryl substrates, the N-phenyl 
sulfonimidates 11 and 12 were selected as test substrates to 
probe sulfoximine formation by Grignard addition (Table 1). 
Initially, the reaction was attempted using the conditions re-
ported by Cram,8a namely the addition of 5 equiv. of Grignard 
at 25 oC in Et2O. Under these conditions the desired product 36 
was obtained in 52% yield. Next the reaction was attempted at 
-78 oC; again with 5 equivalents of Grignard being employed. 
In this case, the desired sulfoximine 36 was obtained in a much 
improved 55% yield. Changing the solvent to toluene caused a 
reduction in yield (48%) and the superior solvent was found to 
be THF (65%). Reducing the equivalents of organometallic to 
three and one equivalents served to reduce the yield (54% and 
31% respectively) as did raising the reaction temperature to -20 
or 0 oC (59% and 41% respectively). The trifluorethyl derived 
sulfonimidate 12 produced lower yields of sulfoximine that the 
ethyl derivative 11. 
 
Figure 3. Synthesis of sulfoximines from the sulfonimidate 
11. Reactions were performed on a 0.1-0.2 mmol scale. Yields 
are for isolated products following chromatography. 
 
With the optimized conditions in hand we set out to investi-
gate the substrate scope of sulfoximine formation with respect 
to the organometallic component (Figure 3). Initially, aryl de-
rived Grignard reagents were trialled (36-46), with product 
yields up to 86% being achieved. Increasing the steric bulk of 
the aryl Grignard from phenyl to biphenyl or mesityl led to an 
erosion in yield (41% and 45% respectively). Introduction of 
heteroaryl Grignards was also demonstrated to be possible with 
the 2-thienyl sulfoximine 39 being obtained in 58% yield. 
Monosubstituted aryl Grignard reagents were utilized with var-
ying success (40-46), the best result was obtained when para-
tolylmagnesium bromide was used (40, 86%). Employing linear 
or branched alkyl (and allyl) derived organometalic reagents al-
lowed access to sulfoximines 47-50 in moderate to good yields 
(30-47% yield), the butyl sulfoximine 49 was accessed using n-
butyl lithium in a moderate yield of 30%. Cycloalkyl moieties 
could also be incorporated; the S-cyclopropyl sulfoximine 52, 
whose core structure can be mapped onto the drug molecule 
AZD 6738 (Figure 1), was generated in 47% yield. Vinyl sul-
foximines have shown utility in the asymmetric synthesis of tet-
rahydrofurans,12 oxabicycles13 and pyrrolidines14 and we were 
intrigued to investigate whether they could be produced using 
this methodology. Pleasingly, the vinyl sulfoximine 55 was iso-
lated in 29%. We next investigated the formation of sul-
foximines bearing alternative N- and S-substitution (Figure 4).  
 
Figure 4. Further studies into the substrate scope for the syn-
thesis of sulfoximines from sulfonimidates. Reactions were per-
formed on a 0.1-0.2 mmol scale. Yields are for isolated products 
following chromatography. 
 
Electron donating and withdrawing groups were tolerated 
comparably on N-aryl derivatives; the para-methoxy, -chloro 
and -trifluomethyl sulfoximines 56-58 were obtained in 43-
48%. We next investigated substrates bearing N-alkyl substitu-
ents; N-cyclohexyl, -benzyl, -tert-butyl and -cyclopropyl sul-
foximines 59-61 were formed in moderate yields (36-46%). A 
limit to the methodology was found with trityl sulfoximine 62, 
which we were unable to form under the optimized conditions. 
Pleasingly however, both S- and N-cyclopropyl sulfoximines 63 
and 64 could be obtained using this method, in 37% and 40% 
yield respectively. 
In conclusion, a general method for the synthesis of sul-
foximines has been developed that proceeds via C-S bond for-
mation. The procedure utilizes the reaction of organometallic 
reagents with sulfonimidates, a class of compounds that have 
not been widely employed as precursors to sulfoximines. To 
compliment this strategy, the scope of sulfonimidate formation 
via the oxidation of sulfinamides has been expanded to include 
S-alkyl substrates for the first time. 
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